These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 38528257

  • 21. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira HD, Silverberg JI.
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [Abstract] [Full Text] [Related]

  • 22. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
    Blauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI.
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2621-2630. PubMed ID: 39110139
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, Girolomoni G, de Bruin-Weller M, Wollenberg A, Kataoka Y, Remitz A, Beissert S, Mastey V, Ardeleanu M, Chen Z, Gadkari A, Chao J.
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.
    Hagino T, Saeki H, Fujimoto E, Kanda N.
    J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS.
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [Abstract] [Full Text] [Related]

  • 34. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S, Bakakis M, Tsiogka A, Afroditi Kleidona I, Gregoriou S.
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [Abstract] [Full Text] [Related]

  • 35. Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
    Paller AS, Gonzalez ME, Barnum S, Jaeger J, Shao L, Ozturk ZE, Korotzer A.
    Arch Dermatol Res; 2024 Jul 30; 316(8):497. PubMed ID: 39080094
    [Abstract] [Full Text] [Related]

  • 36. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T, Hamada R, Yoshida M, Saeki H, Fujimoto E, Kanda N.
    Clin Drug Investig; 2024 Apr 30; 44(4):261-269. PubMed ID: 38446396
    [Abstract] [Full Text] [Related]

  • 37. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZN, Wittmann M.
    Health Technol Assess; 2024 Jan 30; 28(4):1-113. PubMed ID: 38343072
    [Abstract] [Full Text] [Related]

  • 38. Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis.
    Hagino T, Yoshida M, Hamada R, Saeki H, Fujimoto E, Kanda N.
    J Dermatolog Treat; 2024 Dec 30; 35(1):2291317. PubMed ID: 38073560
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, Clark M, Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A.
    Br J Dermatol; 2019 Oct 30; 181(4):761-769. PubMed ID: 30729499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.